Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Short-term Investments (2021 - 2025)

Caribou Biosciences (CRBU) has disclosed Short-term Investments for 5 consecutive years, with $136.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Short-term Investments fell 30.63% to $136.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $136.1 million, a 30.63% decrease, with the full-year FY2024 number at $193.2 million, down 30.4% from a year prior.
  • Short-term Investments was $136.1 million for Q3 2025 at Caribou Biosciences, down from $158.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $277.7 million in Q4 2023 to a low of $135.4 million in Q4 2021.
  • A 5-year average of $198.9 million and a median of $194.7 million in 2024 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: soared 46.66% in 2023, then plummeted 30.63% in 2025.
  • Caribou Biosciences' Short-term Investments stood at $135.4 million in 2021, then soared by 39.81% to $189.3 million in 2022, then soared by 46.66% to $277.7 million in 2023, then plummeted by 30.4% to $193.2 million in 2024, then fell by 29.56% to $136.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Short-term Investments are $136.1 million (Q3 2025), $158.7 million (Q2 2025), and $179.0 million (Q1 2025).